FDA - Testing HCT/P Donors for Relevant Communicable Disease Agents and Diseases
Recommendation
9/10 October 2024
Berlin, Germany
An Overview and Insight in Pharmaceutical Biotechnology
Register now for ECA's GMP Newsletter
On 20 June, the U.S. Food and Drug Administartion has updated their page about "Testing HCT/P Donors for Relevant Communicable Disease Agents and Diseases". On this page the FDA gives an overview about:
- Licensed Donor Screening Tests
- Cleared Nucleic Acid Tests (NAT) for Chlamydia trachomatis and Neisseria gonorrhea
- Cleared Donor Screening Tests for Cytomegalovirus (CMV)
- Cleared Tests for Syphilis
Furthermore they refer to other relevant guidelines and documents:
Additional Resources
- Tissue Safety & Availability
- Tissue & Tissue Products
- Cellular & Gene Therapy Products
Information about tests currently recommended to adequately and appropriately reduce the risk of transmission of relevant communicable disease agents and diseases under 1271.80:
- Testing HCT/P Donors: Specific Requirements
- Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (8/8/2007)
- Blood Donor Screening Tests
Related GMP News
28.08.2024The Effectiveness of Disinfectant Agents: An Overview
21.08.2024Revision of USP <1085> "Guidelines on Endotoxin Test"
05.06.2024Handling of Microbiological Deviations and Sterility Testing - FDA publishes Warning Letter
07.05.2024HTS/NGS - Draft Ph.Eur. Chapter "High-Throughput Sequencing for detecting Viral Extraneous Agents"
31.01.2024EMA publishes new questions and answers on Annex 1
21.11.2023Interpretation of Annex 1 - Swissmedic publishes Q&A Document